Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 8Gynecologic 5Thoracic 3CNS 3Other solid neoplasm 2Dermatologic 2Head & Neck 1

Conditions

Pancreatic Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 60Carboplatin 55Cyclophosphamide 47Pemetrexed 45Irinotecan 33pembrolizumab 32Paclitaxel 29Etoposide 29Gemcitabine 28Nivolumab 24Bevacizumab 24Interviews as Topic 23Vincristine 22Capecitabine 22Topotecan 20Filgrastim 20Early Intervention, Educational 20fludarabine 19Oxaliplatin 19Docetaxel 19Specimen Handling 18Drug Therapy 18Temozolomide 17Sorafenib 17Leucovorin 17Everolimus 17Educational Status 17Radiotherapy 16Methods 16Fluorouracil 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × defactinib × Other solid neoplasm × Clear all
NCT04201145 2020-11-17

Pembrolizumab + Defactinib In Pleural Mesothelioma

Dana-Farber Cancer Institute

Phase 1 Withdrawn
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT02758587 2018-03-19

Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)

NHS Greater Glasgow and Clyde

Phase 1/2 Unknown
59 enrolled
GastrointestinalOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡